Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Results of the Phase I trial of oral Bemiparin based on the OCAP technology
Fri, 14/01/2011 - 08:31
0 min
Download related document
Select rating
Give Results of the Phase I trial of oral Bemiparin based on the OCAP technology 1/5
Give Results of the Phase I trial of oral Bemiparin based on the OCAP technology 2/5
Give Results of the Phase I trial of oral Bemiparin based on the OCAP technology 3/5
Give Results of the Phase I trial of oral Bemiparin based on the OCAP technology 4/5
Give Results of the Phase I trial of oral Bemiparin based on the OCAP technology 5/5
No votes yet
Related
ROVI informs on the evaluation process to obtain marketing authorisation for...
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023
ROVI’s Alcalá de Henares plant receives the visit of the Romanian Health...
Madrid, 6th February, 2023 This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares....
2 min
06/02/2023
ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in...
Madrid: 28 of December 2022 The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022
See More
Email
Facebook
Twitter
LinkedIn